Cas:124782-95-2 6-bromo-2-piperazin-1-ylquinoline manufacturer & supplier

Chemical Name:6-bromo-2-piperazin-1-ylquinoline

CAS.NO:124782-95-2

Synonyms:Quinoline,6-bromo-2-(1-piperazinyl);6-bromo-2-piperazin-1-yl-quinoline;6-Bromoquipazine

Molecular Formula:C₁₃H₁₄BrN₃

Molecular Weight:292.17400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:451.8ºC at 760mmHg

Density:1.451g/cm3

Index of Refraction:1.65

PSA:28.16000

Exact Mass:291.03700

LogP:2.80070

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Quinoline,6-bromo-2-(1-piperazinyl) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Bromoquipazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-bromo-2-piperazin-1-yl-quinoline Use and application,6-bromo-2-piperazin-1-yl-quinoline technical grade,usp/ep/jp grade.

Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 6-bromo-2-piperazin-1-ylquinoline manufacturer With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. 6-bromo-2-piperazin-1-ylquinoline supplier In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 6-bromo-2-piperazin-1-ylquinoline vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 6-bromo-2-piperazin-1-ylquinoline factory In order to seize the highest point of profits, international industry giants have adjusted their development strategies, concentrated their energies on the two ends of the smile curve-research and development and end products, and shifted production links such as intermediates and APIs outward. A division of labor model has been formed.